+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07885475

Evaluating Dexmedetomidine as an Add-On Treatment for Uncontrolled Pain in Palliative Cancer Patients

Led by St. Olavs Hospital · Updated on 2026-10-21

30

Participants Needed

4

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate whether adding dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, can be a safe and effective additional treatment for palliative cancer patients who have pain not well controlled by standard pain medicines like opioids. The study focuses on 30 adult patients with refractory cancer pain who are about to begin dexmedetomidine treatment. Dexmedetomidine is used in intensive care as a sedative and analgesic-sparing drug, but its use for refractory cancer pain is off-label and evidence is limited. Participants will receive dexmedetomidine as an add-on treatment to their usual pain management. The study is observational and will monitor patients during their treatment with dexmedetomidine, recording doses from baseline through day 5 and any dose changes for up to 6 months. Safety and efficacy will be assessed throughout the treatment period. During the study, researchers will evaluate pain intensity over the first 5 days and track adverse events and dexmedetomidine dosing during the entire follow-up period of up to 6 months. Participants will be observed for any side effects and treatment adjustments. The study aims to establish better evidence on the use of dexmedetomidine for refractory cancer pain while ensuring patient safety.

CONDITIONS

Brief Title

Dexmedetomidine for Refractory Pain in Palliative Cancer Patients

Research Team

R

Ragnhild H Habberstad, M.D p.HD

M

Morten Thronæs, M.D pHD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here